BioNTech SE
BNTX
$96.34
-$0.93-0.96%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -786.05% | -171.78% | -117.67% | -112.20% | -98.16% |
Total Depreciation and Amortization | 57.15% | 61.67% | 60.12% | 70.79% | 55.63% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -15.58% | 50.53% | 77.71% | 89.32% | 79.38% |
Change in Net Operating Assets | -89.97% | -78.44% | -48.69% | -44.07% | 47.82% |
Cash from Operations | -104.28% | -96.40% | -71.95% | -66.99% | -31.62% |
Capital Expenditure | -4.31% | -14.56% | -2.83% | 9.40% | 16.44% |
Sale of Property, Plant, and Equipment | -- | -- | 166.68% | -64.55% | -- |
Cash Acquisitions | 77.47% | -- | 100.00% | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 122.38% | 71.51% | -33.84% | -98.27% | -1,001.61% |
Cash from Investing | 116.70% | 69.82% | -21.51% | -98.32% | -724.47% |
Total Debt Issued | -- | -- | -33.33% | -50.00% | -62.50% |
Total Debt Repaid | -33.42% | -13.61% | -36.46% | -38.26% | 0.26% |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -- | -- | 99.90% | 73.36% | 64.01% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 89.67% | 94.12% | 93.78% | 68.26% | 71.18% |
Foreign Exchange rate Adjustments | -137.46% | 215.44% | -725.33% | -112.75% | 225.41% |
Miscellaneous Cash Flow Adjustments | -44.69% | -98.06% | 38,089.00% | 29,675.30% | 21,142.98% |
Net Change in Cash | 137.21% | 11.32% | -5,620.30% | -183.48% | -156.01% |